Latest Sustainable Growth News

Qualitas Limited has announced the early release of over 30 million shares from voluntary escrow, significantly increasing the free float ahead of schedule and potentially enhancing market liquidity.

BetMakers Technology Group delivered a standout Q4 FY25 with record adjusted EBITDA and improved margins, while announcing a strategic acquisition to deepen its US market presence.

Sheffield Resources reported record quarterly production and positive operating cashflow at its Thunderbird Mine, while progressing its South Atlantic Project in Brazil with a maiden resource estimate and key approvals.

Future Generation Global has reported a robust 24.7% total shareholder return over 12 months alongside an increased fully franked interim dividend of 8.0 cents per share, underscoring its growing income stream.

Elsight Limited reports unprecedented revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market demand. The company is on track to achieve profitability in the second half of the year.

Veris Limited has secured a major contract worth up to $20 million to provide engineering survey services for Melbourne’s Suburban Rail Loop East tunnels, boosting its secured workload to over $65 million.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

AMP Limited reports a strong second quarter with Platforms net cashflows soaring 63.2% and Superannuation & Investments achieving positive net cashflows for the first time since 2017. AMP Bank remains steady amid ongoing innovation and market volatility.

Pentanet Limited has secured a $2 million finance facility to fund the final payment for its 5G spectrum licence, reinforcing its growth strategy in telecommunications and cloud gaming.

Connexion Mobility reported steady revenue growth and a 7% increase in net profit before tax for Q4 FY25, driven by expanding SaaS subscriptions and strategic product enhancements.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.

BPH Global Ltd reports a 17.7% revenue increase to A$177,316 in its second month of seaweed sales from Indonesia, signaling early commercial traction and sustainable growth potential.